The interaction between hyperuricemia and low-density lipoprotein cholesterol increases the risk of 1-year...

Area of Science:

• Cardiology
• Metabolic Syndrome
• Clinical Research

Background:

• Hyperuricemia is a recognized cardiovascular disease risk factor.
• The interplay between hyperuricemia and LDL cholesterol in ST-segment elevation myocardial infarction (STEMI) outcomes remains unclear.
• Understanding this interaction is crucial for predicting post-discharge mortality in STEMI patients.

Purpose of the Study:

• To investigate the combined effect of hyperuricemia and low-density lipoprotein cholesterol (LDL-c) levels on 1-year all-cause mortality in STEMI patients.
• To determine if LDL-c modifies the association between hyperuricemia and adverse outcomes after STEMI.
• To analyze the interaction between these two biomarkers in predicting long-term mortality.

Main Methods:

• A cohort of 1396 STEMI patients was analyzed.
• Cox proportional hazards models were employed to assess mortality risk.
• Patients were stratified based on LDL-c levels (<3.0 mmol/L and ≥3.0 mmol/L) to evaluate subgroup-specific effects.

Main Results:

• Hyperuricemia was independently associated with increased 1-year all-cause mortality (HR: 2.66).
• This association was significant only in patients with LDL-c levels ≥3.0 mmol/L (HR: 12.90), not in those with LDL-c <3.0 mmol/L (HR: 0.91).
• A significant interaction between hyperuricemia and LDL-c levels was observed regarding 1-year mortality.

Conclusions:

• Hyperuricemia significantly elevates 1-year mortality risk in STEMI patients with elevated LDL-c (≥3.0 mmol/L).
• No increased mortality risk was observed for hyperuricemic patients with lower LDL-c levels (<3.0 mmol/L).
• The interaction between hyperuricemia and LDL-c is a critical determinant of post-STEMI survival.